RVNC - Revance's lead candidate successful in late-stage study in neck movement disorder

Topline data from Revance Therapeutics's (RVNC) from ASPEN-1 Phase 3 trial evaluating DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia, showed that the study met its primary efficacy endpoint at both doses (125 unit and 250 unit), as well as was generally safe and well-tolerated at both doses, with an encouraging safety profile.Data demonstrated a clinically meaningful improvement in the signs and symptoms of cervical dystonia at the average of Weeks 4 and 6.Compared to placebo, subjects treated with either 125 units or 250 units showed a statistically significant greater change from baseline (12.7 and 10.9 respectively vs. 4.3), as measured on a composite score evaluating features of the cervical dystonia condition, including severity, disability and pain.Median duration of effect was 24.0 and 20.3 weeks, for the 125 Unit and 250 Unit dose groups respectively. The company expects results from the companion ASPEN open-label Phase 3 study, which enrolled 354 subjects, in 2021.Data

For further details see:

Revance's lead candidate successful in late-stage study in neck movement disorder